<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38547">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957722</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-G-H-1220</org_study_id>
    <nct_id>NCT01957722</nct_id>
  </id_info>
  <brief_title>NOVOCARTÂ®3D for Treatment of Articular Cartilage of the Knee</brief_title>
  <acronym>N3D</acronym>
  <official_title>A Phase 3, Prospective, Randomized, Partially Blinded Multi-Center Study to Measure the Safety and Efficacy of NOVOCART 3D Compared ot Microfracture in Teh Treatment of Articular Cartilage Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculap Biologics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculap Biologics, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to  NOVOCART 3D relative to Microfracture for the treatment of knee cartilage
      defects. Efficacy will be evaluated by both pain and function. Safety will also be
      evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with articular knee defects will be randomized to receive either Microfracture or
      NOVOCART 3D.  Subjects will be followed for five years in total and will be evaluated for
      safety and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>24 months post treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>As measured by change in score from Baseline in KOOS score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Function</measure>
    <time_frame>24 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured by change in score from Baseline in KOOS score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">233</enrollment>
  <condition>Articular Cartilage of the Femoral Condyle Between 4-6cm2</condition>
  <arm_group>
    <arm_group_label>NOVOCART 3D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scaffold assisted autologous chondrocyte Implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microfracture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>considered a typical treatment for articular cartilage repair</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>microfracture</intervention_name>
    <description>Surgical procedure which creates a marrow clot in the prepare cartilage defect.</description>
    <arm_group_label>Microfracture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NOVOCART 3D</intervention_name>
    <arm_group_label>NOVOCART 3D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 18 years old

          -  Isolated articular cartilage lesions on the femoral condyle 2-6 cm2

          -  Minimum score on the KOOS questionnaire

        Exclusion Criteria:

          -  Instability of the knee joint

          -  Arthritis

          -  Autoimmune disease

          -  Immune suppression

          -  Prior surgical treatment using mosaicplasty, autologous chondrocyte implantation
             and/or microfracture (debridement and lavage are acceptable beyond three months from
             baseline)

          -  Bone disease

          -  Any degenerative muscular, connective tissue or neurological condition or other
             disease process that would interfere with healing or the evaluation of outcome
             measures.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kerlan Jobe Orthopedic Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Goldsmith</last_name>
      <phone>310-665-7200</phone>
      <phone_ext>6255</phone_ext>
      <email>laura.goldsmith@kerlanjobe.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Gambardella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glynn Brunswick Memorial Authority/ SE Georgia Health System</name>
      <address>
        <city>Brunswick</city>
        <state>Georgia</state>
        <zip>31525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwen Gratto-Cox</last_name>
      <phone>912-262-9961</phone>
      <phone_ext>122</phone_ext>
      <email>ggratto@sghs.org</email>
    </contact>
    <investigator>
      <last_name>Melvin Deese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Orthopedics</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Thorpe</last_name>
      <phone>804-527-6803</phone>
      <email>lthorp@advancedortho.me</email>
    </contact>
    <investigator>
      <last_name>Kenneth Zaslav</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>September 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
